Researchers at MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
